



## UCB completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline

- **Cizutamig, Candid's lead investigational asset and a potential best-in-class BCMA T-cell engager, now advances as part of UCB's growing innovative immunology pipeline**
- **Reinforces UCB's platform-driven immunology strategy, strengthening and further diversifying next-generation biologics capabilities and expanding approach across multiple antibody-mediated diseases**

**Brussels (Belgium), 17 June, 2026, 07:00 (CEST)** – UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the successful completion of its previously announced acquisition of Candid Therapeutics (Candid), a clinical-stage biotechnology company developing novel T-cell engager (TCE) therapies for autoimmune and inflammatory diseases.

The acquisition strengthens UCB's position as an innovator in immunology and expands its capabilities in next-generation biologics aimed at achieving immune reset. It brings cizutamig, Candid's lead investigational asset, into UCB's pipeline. Cizutamig is a bispecific antibody targeting B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells, designed to enable T-cell-mediated depletion of pathogenic B-cell populations. The asset is currently being evaluated in multiple Phase 1 clinical studies across a range of autoimmune diseases.

The total transaction is valued at up to US \$2.2 billion, consisting of US \$2 billion in upfront payments, plus up to US \$200 million in potential future milestone payments.

Cizutamig is an investigational drug that has not been approved by the FDA or other health authorities.

### **About UCB**

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB).

### **Forward-looking statements**

This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring, retention and compliance of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products





will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

**For further information, contact UCB:**

**Global R&D Communications**

Scott Fleming

T: +44.770.277.7738

[Scott.fleming@ucb.com](mailto:Scott.fleming@ucb.com)

Ines Garces de los Fayos Alonso

T: +32.477.175861

[ines.garcesdelosfayosalonso@ucb.com](mailto:ines.garcesdelosfayosalonso@ucb.com)

**Corporate Communications, Media Relations**

Laurent Schots

T +32.2.559.92.64

[laurent.schots@ucb.com](mailto:laurent.schots@ucb.com)

**Investor Relations**

Yvonne Naughton

T +44.175.344.7521

[yvonne.naughton@ucb.com](mailto:yvonne.naughton@ucb.com)

Sahar Yazdian

T +32.2.559.94.37

[sahar.yazdian@ucb.com](mailto:sahar.yazdian@ucb.com)

